A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
05/2011
05/19/2011	US20110118246 Novel Compounds
05/19/2011	US20110118245 Raf kinase modulator compounds and methods of use thereof
05/19/2011	US20110118238 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
05/19/2011	US20110118237 Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof
05/19/2011	US20110118233 Certain Substituted Amides, Method of Making, and Method of Use Thereof
05/19/2011	US20110118230 Diazacarbazoles and methods of use
05/19/2011	US20110118228 Enzymatic production or chemical synthesis and uses for 5,7-dienes and UVB conversion products thereof
05/19/2011	US20110118226 Transdermal pharmaceutical compositions comprising danazol
05/19/2011	US20110118225 Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them
05/19/2011	US20110118219 Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
05/19/2011	US20110118211 Novel glucokinase activators and methods of using same
05/19/2011	US20110118209 Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
05/19/2011	US20110118208 Thiazolyl-Dihydro-Indazoles
05/19/2011	US20110118207 Modified hydroxypolymer conjugates with bone seeking and tumor killing moieties
05/19/2011	US20110118205 Anti-tumor agent comprising cytidine derivative and carboplatin
05/19/2011	US20110118200 A pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system
05/19/2011	US20110118199 Use of cns penetrating anticancer compounds for the treatment of protozoal diseases
05/19/2011	US20110118193 Treatment of liquid cancers
05/19/2011	US20110118192 Methods and compositions for treating t-cell leukemia
05/19/2011	US20110118191 Crotoxin Administration for Cancer Treatment and Pain Relief
05/19/2011	US20110118185 Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
05/19/2011	US20110118172 Metastin derivative and use thereof
05/19/2011	US20110117569 Polymide nucleic acid derivatives, and agents and processes for preparing them
05/19/2011	US20110117216 Anti-tumoural effects of cannabinoid combinations
05/19/2011	US20110117212 Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
05/19/2011	US20110117211 Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa
05/19/2011	US20110117210 Therapeutic treatment of human cancers using simple salts of zinc
05/19/2011	US20110117197 Sustained-release drug carrier composition
05/19/2011	US20110117187 Topical compositions and methods for epithelial-related conditions
05/19/2011	US20110117186 Intravenous infusion of curcumin and a calcium channel blocker
05/19/2011	US20110117183 Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors
05/19/2011	US20110117164 Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers
05/19/2011	US20110117141 Methods and compositions comprising novel cationic lipids
05/19/2011	US20110117137 Tapasin augmentation for enhanced immune response
05/19/2011	US20110117135 Method of Forming Dendritic Cells from Embryonic Stem Cells
05/19/2011	US20110117124 Enhancement of transgene expression from viral-based vaccine vectors by expression of suppressors of the type i interferon response
05/19/2011	US20110117117 Novel immunogenic epitopes for immunotherapy
05/19/2011	US20110117115 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
05/19/2011	US20110117114 Neovascular-Targeted Immunoconjugates
05/19/2011	US20110117113 Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
05/19/2011	US20110117110 Anti-egfr antibodies and their uses
05/19/2011	US20110117108 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
05/19/2011	US20110117105 Method of treating immune disease using b-cell antibodies
05/19/2011	US20110117098 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
05/19/2011	US20110117097 Her2 antibody composition
05/19/2011	US20110117096 Methods for Identifying Tumors That are Responsive to Treatement With Anti-ErbB2 Antibodies
05/19/2011	US20110117090 Adam-15 antibodies and immunogenic peptides
05/19/2011	US20110117089 BCR-Complex-Specific Antibodies And Methods Of Using Same
05/19/2011	US20110117088 Composition and method for introduction of rna interference sequences into targeted cells and tissues
05/19/2011	US20110117086 Monoclonal antibodies to progastrin and their uses
05/19/2011	US20110117085 Monoclonal antibodies for tumor treatment
05/19/2011	US20110117084 Vandetanib derivatives
05/19/2011	US20110117083 Biological markers for monitoring patient response to vegf antagonists
05/19/2011	US20110117081 Functionalized pyrrolidines and use thereof as iap inhibitors
05/19/2011	US20110117079 Therapeutic dll4 binding proteins
05/19/2011	US20110117078 Methods for the Treatment of Cancers
05/19/2011	US20110117073 Protein Kinase Conjugates and Inhibitors
05/19/2011	US20110117069 Method for activating regulatory t-cells
05/19/2011	US20110117060 Cancer treatment using viruses, fluoropyrimidines and camptothecins
05/19/2011	US20110117059 Composition of soluble indigestible fibre and of microalgae used in the well-being field
05/19/2011	US20110117052 Methods of treatment using il-31ra
05/19/2011	US20110117051 Method for inducing and accelerating cells
05/19/2011	US20110117050 Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen
05/19/2011	US20110117029 Water-soluble anionic bacteriochlorophyll derivatives and their uses
05/19/2011	US20110117026 Methods and compositions for the delivery of bioactive compounds
05/19/2011	US20110117024 Nanocarrier and nanogel compositions
05/19/2011	US20110117017 Peptides with properties of an allosteric antagonist selective for the alpha 1a adrenergic receptor and uses thereof
05/19/2011	US20110117016 Diagnostic compounds
05/19/2011	US20110117013 Compositions against cancer antigen liv-1 and uses thereof
05/19/2011	US20110117010 Methods and Compositions for Administering Therapeutic and Diagnostic Agents
05/19/2011	US20110117009 Drug conjugates with polyglycerols
05/19/2011	US20110117008 Use of avicins to deliver therapeutic and diagnostic agents
05/19/2011	CA2817198A1 Compositions and methods for treating hyperproliferative disorders
05/19/2011	CA2812929A1 Compositions and methods for treating hyperproliferative disorders
05/19/2011	CA2789879A1 Dimeric smac mimetics
05/19/2011	CA2780892A1 Kinase inhibitors
05/19/2011	CA2780773A1 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
05/19/2011	CA2780723A1 Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
05/19/2011	CA2780708A1 Single-chain variable fragment (scfv) able to recognize and bind cd99 human protein
05/19/2011	CA2780633A1 Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
05/19/2011	CA2780547A1 Spiro-oxindole mdm2 antagonists
05/19/2011	CA2780495A1 Tivozanib and temsirolimus in combination
05/19/2011	CA2780457A1 Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
05/19/2011	CA2780365A1 Mammalian metabolites of steroids
05/19/2011	CA2780282A1 Homoglutamic acid derivatives
05/19/2011	CA2780243A1 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
05/19/2011	CA2780031A1 A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
05/19/2011	CA2780018A1 N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
05/19/2011	CA2779843A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
05/19/2011	CA2779683A1 Anti-c-mpl antibodies
05/19/2011	CA2779508A1 Method and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
05/19/2011	CA2778693A1 Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
05/19/2011	CA2778686A1 N-9-substituted purine compounds, compositions and methods of use
05/19/2011	CA2778175A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
05/19/2011	CA2776829A1 Compounds for pim kinase inhibition and for treating malignancy
05/19/2011	CA2775373A1 Antibodies specific for claudin 6 (cldn6)
05/18/2011	EP2322933A1 Diagnosis of carcinomas
05/18/2011	EP2322929A1 Diagnostics, drug screening and treatment for cancer
05/18/2011	EP2322628A2 Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
05/18/2011	EP2322627A2 Mutations in the BCR-abl tyrosine kinase associated with resistance to STI-571

1 ... 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 ... 2211